Treatment Information

Back

Colon Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, New York
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Apr 2004

Description:

Patients: This Phase II trial involved 57 patients with metastatic colorectal cancer. Patients were required to have received a chemotherapy drug (irinotecan), either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before becoming involved in this study. In addition, the tumors of all patients had EGFR. (EGFR is epidermal growth factor receptor. It is expressed in many normal tissues and over expressed in some tumors.)

Treatment: Treatment consisted of the monoclonal antibody, cetuximab.

Toxicity: Grade 3-4 toxicities included: acne, allergic reaction, asthenia, atrial fibrillation, confusion, diarrhea, headache, hypokalemia, rash, and vomiting.

Results: Median survival was 6.4 months.

Support: Four of the authors of this study either act as a consultant for Imclone and/or Bristol-Myers Squibb, performed contract work for these companies, served as an officer or board member of these companies, and/or received compensation from these companies. Both Imclone and Bristol-Myers Squibb are involved in the marketing of cetuximab (Erbitux).

Correspondence: Leonard B. Saltz, MD





Back